Sector News

Alexion brings on former Baxalta chief Hantson to fill vacant CEO spot

March 28, 2017
Life sciences

Alexion’s CEO search is over. The Connecticut biotech, which bade its skipper farewell late last year, is bringing former Baxalta chief Ludwig Hantson into the fold.

Hantson will take the reins from David Brennan, who stepped in as interim CEO after David Hallal made his exit last December. Brennan will remain on Alexion’s board, which expects to appoint him chairman at the company’s mid-May annual meeting, Alexion said.

All eyes will be on the newcomer CEO, who will be tasked with helping Alexion move on after an investigation that found that, to hit financial targets, former execs pressed staffers to get customers to place their orders of lead med Soliris earlier than they would have otherwise. During that probe, both Hallal and then-CFO Vikas Sinha left the company, with one source telling CNBC that the pair had lost the confidence of Alexion’s board.

Meanwhile, Hantson’s experience in the rare-disease field will come in handy at Alexion, whose marketed products are used to treat orphan diseases such as paroxysmal nocturnal hemoglobinuria and lysosomal acid lipase deficiency. Baxalta’s hemophilia prowess is what drew rare-disease drugmaker Shire’s attention, and its 2016 buyout of the Baxter spinoff put Hantson out of a job.

He’ll need to lean on that know-how early, with plenty of near-term events on Alexion’s horizon. Among them: regulatory decisions in the U.S. and EU for Soliris in refractory generalized myasthenia gravis, an indication that could kick in about $200 million in additional sales by 2020, Barclays analyst Geoff Meacham has predicted.

On his resume, Hantson has more than the stint at short-lived Baxalta, which stood on its own for less than a year before the $32 billion Shire deal closed. He held a number of roles with Novartis—including CEO of Novartis’ North American pharma division and CEO of Novartis Europe—as part of a decade-long tenure at the Swiss pharma giant.

By Carly Helfand

Source: Fierce Pharma

comments closed

Related News

May 15, 2022

Novo Nordisk and Flagship Pioneering announce a strategic collaboration to create a portfolio of transformational medicines

Life sciences

The companies will explore opportunities to apply Flagship’s innovative bioplatforms – an ecosystem that currently comprises 41 companies – to scientific challenges in disease areas within cardiometabolic and rare diseases and initiate research programmes based on these.

May 15, 2022

BD, Babson set sights on bringing simple blood collection into the home

Life sciences

BD is expanding its long-running partnership with the blood collection company Babson Diagnostics. The two companies have been working together since 2019 on a device that can gather small volumes of blood from the capillaries in the fingertip without requiring any specialized training, and beginning with a focus on supporting primary care in retail settings.

May 15, 2022

CSL’s $11.7B Vifor buy, 2021’s biggest biopharma M&A deal, hits antitrust delay

Life sciences

Wednesday, Australian biotech CSL said (PDF) the regulatory review of its $11.7 billion acquisition of Switzerland’s Vifor Pharma will take “a few more months,” suggesting it won’t be able to close the transaction by June 2022 as previously expected.